CKD Treatment: Addressing Kidney and Cardiometabolic Outcomes Part 2: SGLT2 inhibitors
SGLT2 inhibitors are an addition to our pharmacotherapy toolkit that have cardio- and kidney-protective benefits for individuals with kidney disease. New information from clinical trials has prompted guideline updates from leading diabetes and nephrology organizations. In this module, we will review the supporting evidence and guidelines in addition to discussing clinical considerations for the optimal use of SGLT inhibitors in improving cardiometabolic and kidney outcomes.
By the end of this module, learners will be able to:
- Describe current recommendations/guidance for SGLT-2i use
- Review proposed mechanisms of cardio- and kidney-protective effects of SGLT-2is
- Summarize supporting evidence for SGLT-2is in slowing CKD progression, reducing albuminuria & cardiovascular risk
- Apply guideline-directed medication therapy to initiate, monitor, and modify SGLT-2i use
- Outline strategies to improve pharmacoequity in use of SGLT-2is
Time: 30 minutes
The following planners and presenters have disclosed a financial relationship with an ineligible company:
- Katie Cardone, PharmD, BCACP, FNKF, FASN, FCCP - Grants/Research Support [Merck & Co], Consultant [Vifor, Otsuka], Honorarium [Pharmacy Times]
- Calvin Meaney, PharmD, BCPS - Speaker's Bureau [GSK], Consultant [GSK, Wolters-Kluwer (Lexicorp)]
- Wendy St. Peter, FCCP, FASN, FNKF - Consultant [GSK]
There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.
All relevant financial relationships have been mitigated.
In support of improving patient care, this activity is planned and implemented by The National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD). The OICPD is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians: The National Center for Interprofessional Practice and Education designates this live activity for . 5 hours AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with their participation.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Nurses: Participants will be awarded .5 contact hours of credit for attendance in this module.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists: This activity is approved for .5 contact hours. UAN: JA4008105-9999-23-027-H01-P.
IPCE: This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credits for learning and change.
